Eli Lilly: new Weight Loss Pill Shows Significant Effect – but not Quite as Hoped!

Eli Lilly has released new study results on the oral GLP-1 candidate Orforglipron. In a Phase III study, overweight participants without diabetes lost an average of 12.4% of their body weight within 72 weeks. These results mark an important step in the development of non-invasive treatment options for obesity. Manageable side effects – approval process underway The highest effects were observed at the 36 mg dosage, while the lowest tested dose (6 mg) achieved an average weight reduction of 7.8%. Side effects such as nausea and vomiting primarily...